Deep learning enables to clarify the association of osteoporosis risk with bone metastasis in premenopausal women after surgery for early-stage breast cancer: multicenter retrospective cohort study

Hirokazu Shimizu[1,2,3*], Nobumoto Tomioka[4], Akira Iwata[2], Chinatsu Koganezawa[4] , Tomohiro Oshino[5], Kenichi Watanabe[4], Mitsugu Yamamoto[4], Hiroaki Hiraga[2], Shinya Tanaka[3,6,7], Masato Takahashi[5] and Norimasa Iwasaki[1].

Authors' affiliations:

[1]Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

[2]Department of Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan

[3]Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan

[4]Department of Breast Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan

[5]Department of Breast Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

[6]Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan

[7]Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

***Corresponding author: Hirokazu Shimizu**

[1]Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

e-mail: shimizu_hirokazu@nifty.com

Tel.: +81-11-716-1161

Fax: +81-11-706-6054

Key words: breast cancer, bone metastasis, premenopausal women, osteoporosis

Abstract

Background: Whereas one-quarter of premenopausal women might have osteopenia, dual-energy Xray absorptiometry (DXA) are omitted to those with early-stage breast cancer (eBC). To this, rapid advances of deep learning (DL) have enabled to evaluate their risk of osteoporosis (RO) by utilizing perioperative chest radiography. Although osteoporosis fundamentally provide fertile premetastatic niches, the association of osteoporosis with bone metastasis (BM) remains unknown. This study aimed to clarify the association in women after eBC surgery, and to perform the stratified analysis by menopause status.

Methods: This multicenter retrospective cohort study enrolled 785 women who had surgery for stage 2-3 estrogen receptor-positive breast cancer from 2007 to 2019, excluding cases with adjuvant use of bone-modifying agent (BMA). Perioperative chest radiography was input to DL producing RO score (0-1). They were classified by the score into 359 women with low-risk of osteoporosis (LRO) and 426 with high-risk (HRO). 5-year BM-free survival (BMFS) was compared by cox-hazard proportional models.

Findings:

The multivariate analyses for the enrolled women (median [interquartile range] age, 56 [46-66] years) identified RO as a poor prognostic factor (hazard ratio [HR] 4.23, 95% confidence interval [CI]; 1.71-10.13, $p<0.01$). The stratification analyses by menopausal status revealed that the number of the premenopause was 325, discovering HRO (23.1% [75/325]) in the premenopause was associated with low BMFS (HR2.53, 95% CI; 1.37-4.67, $p<0.01$) whereas no association was observed in the others ($p=0.71$). The conduction rate of DXA was lower in premenopause (31/325 vs 317/461, $p<0.01$).

Interpretation: RO is an independent prognostic factor for BM in the enrolled women with eBC. This study discovered the association of RO with BM specifically in premenopausal women with eBC, whose bone health have been poorly checked. An expanded indication of adjuvant use of BMA is suggested to the premenopausal women with the risk.

Funding

No funding was received for this research.

Introduction

Randomized controlled trials (RCTs) on postmenopausal women with early-stage breast cancer (eBC) showed that adjuvant bone-modifying agents (BMA) improved bone metastasis-free survival (BMFS) or disese free-survival[1-3] , while a precise mechanism how BMA regulate occurrence of BM have not fully been understood. An original concept of the adjuvant BMA use for postmenopausal women is to maintain bone density, preventing osteoporosis[2,4,5]. Currently, the US and Europe guidelines states that adjuvant BMA should be discussed with all postmenopausal women with eBC[6,7], while the Japenese guideline suggests the adjuvant use for them if they have the diagnosis of osteporosis[8]. In clinical setting, however, approximately one-quarter or more of premenopause or perimenopause women might have osteopenia[9-11]. In other words, there would also be a certain ratio of pre-menopausal eBC women with osteopenia, but dual-energy Xray absorptiometry (DXA) in perioperative periods have been often omitted to them. To date, it would be difficult to evaluate osteosporosis or osteopenia directly through DXA in the premenopausal women with eBC.

Rapid advances of deep learning (DL) have made it possible to assess accurately risk of osteoporosis (RO) to patients by just using chest radiography[12-14]. It means that the assessment can be performed patients who have had perioperative chest radiography for surgery under general anesthesia[15]. OPSCAN, osteoporotic precise screening using chest radiography and artificial neural network, was developed by 48353 chest radiography correspondent with T-score[13]. As the patients age for the matched data was 20 years or older, those with osteoporosis, osteopenia, and normal range of T-score were widely contained. Further, the efficacy of the model was also confirmed by RCTs which aimed to identify individuals at high risk of

osteoporosis[12]. Crucially, osteoporosis is well-known factor for fragile fracture, but it can be regarded as age-related host environments from the tumor biological perspective.

Recent biomolecular research has been focused on whether conditions altered depending on age of host environment would affect metastatic recurrecne of secondary lesions[16,17]. In lung, one of the most frequent lesions as a secondary site, age-induced reprograming of lung fibroblast promote tumor cell activation and proliferation[16,17]. As bone is well-known as another common secondary site, the activities of osteoclast are also age-dependent[18-20]. Osteolytic metastases such as breast cancer are caused by osteoclast stimulation, which is mobilized by the increased levels of receptor activator of nuclear factor–κB ligand and inflammatory cytokines[21-23]. Meanwhile, high activities of osteoclasts are observed in the osteoporotic bone where the tissue resorption was accelerated[24,25]. Thus, the mechanism of osteoporosis fundamentally provide fertile premetastatic niches for tumor cells in bone[26,27]. In fact, a clinical investigation showed the association of untreated osteoporosis is associated with accelerated progression of bone metastases shold they occur[24]. In addition, bone density itself has emerged as an important risk factor for some cancer[28-31]. However, the association of osteoporosis with bone metastasis remains unknown.

Based on these biomolecular mechanisms, we hypothesized that osteoporosis contribute early recurrence of bone metastases. The aim of this study by utilizing DL is 1) to reveal the association of RO with BM in women with eBC and 2) to perform the stratified analysis by menopausal status. As far as our knowledges, no retrospective cohort studies have utilized the output from deep learning as exposure, uncovering a new risk factor for clinically crucial events and hidden population with the risk.

Methods

Study design and participants

This multicenter retrospective cohort study recruited patients from surgical record for breast cancer from 2007 to 2019 (Figure1). We recruited 862 patients with informed consent who underwent surgery for clinical stage 2-3, estrogen positive, human epidermal growth factor receptor2 (HER2) negative breast cancer, excluding the 77 patients because of men, bilateral breast cancer, no perioperative chest Xray, or adjuvant use of BMA owing to osteoporosis (T-score of -2.5 or low). As a result, 785 women were enrolled in this study.

The study was approved by the local ethics committees of Hokkaido University Hospital (022-0118) and NHO Hokkaido Cancer Center. As all participant agreed on the use of data, informed consents were obtained. Clinical trial number was not applicable to this study. The study was conducted in accordance with the principles of human ethics set forth by the Declaration of Helsinki.

Procedures

The enrolled women were classified by RO estimated by the deep learning application, OPSCAN[12,13] which produce the risk score as continuous variables [0-1]. As the primary outcome of the model is to predict T-score, the higher risk score would correlate lower T-score[13]. The RO score divided them into 359 women with low-risk osteoporosis (LOR) and 426 women with high-risk osteoporosis (HOR). For our original cohort, electronic medical records were used to ascertain clinicopathological characteristics including perioperative chest radiography, bone density test. The data of primary treatments was collected: surgery date, radiotherapy, perioperative chemotherapy, and endocrine therapy. As the primary outcome, the 5-year Bone

metastasis free survival (5-year BMFS) was compared. Cox-hazard proportional model was applied to identify the independent prognostic factors. The stratified analysis was performed by the menopausal status which affect the bone environments.

Statistical analysis

Categorical variables were evaluated using the chi-squared test for two or more groups, whereas continuous variables were analyzed using an independent t-test. The normal distribution of patient age was tested by Shapiro-Wilk test. Survival rates were visualized using the Kaplan–Meier method and differences were investigated using the log-rank test. Cox-hazard proportional model was applied to identify the independent prognostic factors. The stratified analysis was performed by the menopausal status which affect the bone environments. The Pearson correlation coefficient is used to measure linear correlation between two sets of data. We performed all the statistical analyses using JMP Pro version 14 (SAS Institute, Inc., Cary, NC, USA). All test were 2-sided and $p<.05$ was considered to be statistically significant.

Results:

Characteristics of Study Cohort

Baseline characteristics of the enrolled women (median [interquartile range (IQR)] age 56[46-66]) are shown in Table1. HRO were older at surgery than LOR (median [SD] age, 63.0±10.8 vs 48.4±9.3, p<0.01). Rate of Stage 3 was not different in HRO and LRO (101/426 vs 96/359, p<0.33). The rate of perioperative chemotherapy was lower in HRO compared to LRO (199/426 vs 245/359, p<0.01). The rate of endocrine therapy was not different (399/426 vs 226/325, p=0.96). Loss of follow-up during 5 years was 2.2% (17/785).

The 5-year bone metastasis free survival ratio stratified by menopausal status

Univariate analysis showed that HRO was not associated with BM in enrolled women (log-rank test, p=0.05) (Figure 2a). As stratification was conducted by menopausal status, premenopausal women (n=325) contained HRO of 23.1% (75/325) which had lower 5-year BMFS (p<0.01) (Figure 2b), whereas there was no significant difference between the two groups at post-menopausal women(n=460) (p=0.71) (Figure 2c). Menopausal status clearly stratified recurrence of BM. In addition to menopausal status, age, perioperative chemotherapy is known factors for cancer and osteoporosis, we included these variables in the statistical models.

Multivariate analysis

Cox proportional hazard models adjusted by age, menopausal status, and the presence of perioperative chemotherapy demonstrated that RO score was an independent prognostic factor (hazard ratio [HR] 4.23, 95% confidence interval [CI]; 1.71-10.13, p<0.01), as well as the clinical stage (HR 3.32, 95%CI; 2.14-5.16, p<0.001) (Table 2). The models also demonstrated that RO score was an independent poor prognostic factor in postmenopausal women (HR2.87, 95%CI; 1.01-7.99, p=0.04) as well as in premenopausal women (HR8.69, 95%CI; 1.86-30.78, p<0.01)

Dual-energy Xray absorptiometry and risk of osteoporosis

The conduction rate of DXA in the enrolled women was 44.3% (348/785). Importantly, the rate in premenopausal was 9.3% (31/335), whereas the rate in postmenopausal women was 72.0% (317/440) (p<0.001) (Figure3a). In the postmenopausal women, the correlation between the risk

of osteoporosis and T-score was observerd (n=317, r=-0.61, p<0.01) (Figure3b). To ensure the validity of the risk of osteoporosis in premenopausal women, a formula for predicting bone metastasis within 5 months was created using independent prognostic factors; staging and the risk of osteoporosis (Figure 3c). There was a moderate performance of predicting bone metastasis within 5 years after surgery in the premenopausal women with the area under the receiver operating characteristics of 0.71 (Figure 3d).

Discussion

This study showed RO score as an independent prognostic factor for bone metastasis in women with eBC, discovering the clear association of RO with BM especially in premenopausal women. Current clinical settings have let physicians consider adjuvant use of BMA only to postmenopausal women with eBC. In fact, our data showed that the conduction rate of a bone density test was lower than 10 % in premenopausal women, being 72.0% in the others.

The design of the present study has a new perspective for clinical medical research, uncovering the new risk factor and hidden population with the risk. We regarded the output from deep learning application as exposure. In most of previous literature, the designs for retrospective research with the use of deep learning were to evaluate the output from deep learning as a main outcome in the study. However, we considered the output as one of the patient characteristics, uncovering the association of the output and the clinically crucial endpoint.

We discovered the poorly cared population from the perspective of bone environments: premenopausal women with eBC, to whom we suggest the expanded indication of adjuvant BMA. Previous reports stated that breast cancer in premenopausal women are generally aggressive and their prognoses are relatively poor[32] and breast cancer patients aged 40-60 years

olds are prone to BM[33,34]. As the most common first site of distant spread is bone in breast cancer[35], a recent biomolecular research bone revealed that bone environments invigorate metastatic seeds for further dissemination[36]. Thus, preventing bone metastasis is a crucial therapeutic strategy. Further studies should be performed to prospectively confirm the association of T-score in premenopausal eBC women with recurrence of BM as well as clinical benefit of adjuvant BMA use for them.

Outcomes of adjuvant BMA use in postmenopausal women with eBC are controversial[1-3,37]. Those mixed results might be attributed to classifications of patients without consideration of bone density although RCTs can logically adjust unidentified confounding factors[38-40]. Our results showed that RO score is the independent prognostic factor even in postmenopausal women. It suggests the possibility that postmenopausal women with low bone density could have benefit from adjuvant use of BMA more than those with normal range of bone density. Additional studies could be performed to investigate the association of osteoporosis with BM in postmenopausal women with eBC. The present study furtherly implied a substantial benefit of the adjuvant use for patients with low bone density who are diagnosed as solid or liquid cancer causing metachronous bone lesion.

Osteoporosis must be viewed as a pathological condition which affects the entire skeleton[41], while it is defined by DXA of lumbar spine or assessment of RO is performed by chest radiography. Such examinations of a certain skeletal location might have limited ability to the state of the entire skeleton. Further studies using computed-tomography for whole body might reveal the heterogeneity of skeleton status and new aspects for the association with BM.

Several limitations should be discussed. First, this was a retrospective study. The selection bias and recall bias might affect the results. Second, risk of osteoporosis produced by

the machine learning was not strictly consistent with the definition of WHO criteria[42], although the adopted model was trained and developed by the over 48000 images in which the patients age for the matched data was 20 years or older.

Conclusion

Risk of osteoporosis is an independent prognostic factor for bone metastasis in women with early-stage breast cancer. The clear association between risk of osteoporosis and bone metastasis in premenopausal women with early-stage breast cancer was observed. This study with use of deep learning technology discovered the poorly cared population from the perspective of bone environments: premenopausal women with early-stage breast cancer, to whom we suggest an expanded indication for the adjuvant use of bone-modifying agents.

DECLARATIONS

Consent for publication

Not applicable.

Availability of data and materials

Data from this study, including individual participant data, are not available for sharing. Summary statistical data will be available from the corresponding author on reasonable request with the permission.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors contributed to the Article and approved the submitted version. After unmasking of the outcome data, all authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. KT, AI, KW and MT verified the raw data in the study. HS conceptualised the study. HS and NT contributed to the methodology and the formal analysis of the data. HS were responsible for using the data analysis software used in the study. All authors validated the findings of the study. HS contributed to the formal analysis of the data. CK and TO conducted the investigation. NT, KW, MY and MT provided the resources necessary for the study. CK abd TO curated the data. HS wrote the original draft of the manuscript. NI abd MT reviewed and edited the manuscript. HS created the visualisations of the study findings. NI and MT supervised the research activities. TS managed the project administration.

Acknowledgements

Not applicable.

References

1. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology* 2019; **20**(3): 339-51.
2. Gnant M, Frantal S, Pfeiler G, et al. Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. *NEJM Evid* 2022; **1**(12): EVIDoa2200162.
3. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *The Lancet* 2015; **386**(10001): 1353-61.
4. Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. *Lancet Diabetes Endocrinol* 2018; **6**(11): 901-10.

5. Moretti L, Richelmi L, Cosentini D, et al. Adjuvant denosumab for early breast cancer–Evidence and controversy. *The Breast* 2024; **78**: 103826.
6. Eisen A, Somerfield MR, Accordino MK, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. *Journal of Clinical Oncology* 2022; **40**(7): 787-800.
7. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol* 2019; **30**(8): 1194-220.
8. Terada M, Ito A, Kikawa Y, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. *Breast Cancer* 2023; **30**(6): 872-84.
9. Fan Y, Li Q, Liu Y, et al. Sex- and Age-Specific Prevalence of Osteopenia and Osteoporosis: Sampling Survey. *JMIR Public Health Surveill* 2024; **10**: e48947.
10. Shariati-Sarabi Z, Rezaie HE, Milani N, Rezaie FE, Rezaie AE. Evaluation of Bone Mineral Density in Perimenopausal Period. *Arch Bone Jt Surg* 2018; **6**(1): 57-62.
11. Chawla J, Sharma N, Arora D, Arora M, Shukla L. Bone densitometry status and its associated factors in peri and post menopausal females: A cross sectional study from a tertiary care centre in India. *Taiwanese Journal of Obstetrics and Gynecology* 2018; **57**(1): 100-5.
12. Lin C, Tsai D-J, Wang C-C, et al. Osteoporotic Precise Screening Using Chest Radiography and Artificial Neural Network: The OPSCAN Randomized Controlled Trial. *Radiology* 2024; **311**(3): e231937.
13. Tsai DJ, Lin C, Lin CS, Lee CC, Wang CH, Fang WH. Artificial Intelligence-enabled Chest X-ray Classifies Osteoporosis and Identifies Mortality Risk. *J Med Syst* 2024; **48**(1): 12.
14. Ryu J, Eom S, Kim HC, et al. Chest X-ray-based opportunistic screening of sarcopenia using deep learning. *J Cachexia Sarcopenia Muscle* 2023; **14**(1): 418-28.
15. Young EM, Farmer JD. Preoperative Chest Radiography in Elective Surgery: Review and Update. *S D Med* 2017; **70**(2): 81-7.
16. Fane ME, Chhabra Y, Alicea GM, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. *Nature* 2022; **606**(7913): 396-405.
17. Turrell FK, Orha R, Guppy NJ, et al. Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse. *Nature Cancer* 2023; **4**(4): 468-84.
18. Møller AMJ, Delaissé J-M, Olesen JB, et al. Aging and menopause reprogram osteoclast precursors for aggressive bone resorption. *Bone Research* 2020; **8**(1): 27.
19. Yang Q, Wei Z, Wei X, et al. The age-related characteristics in bone microarchitecture, osteoclast distribution pattern, functional and transcriptomic alterations of BMSCs in mice. *Mechanisms of Ageing and Development* 2023; **216**: 111877.
20. Chung PL, Zhou S, Eslami B, Shen L, LeBoff MS, Glowacki J. Effect of age on regulation of human osteoclast differentiation. *J Cell Biochem* 2014; **115**(8): 1412-9.
21. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. *Nature Reviews Cancer* 2009; **9**(4): 274-84.
22. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer* 2002; **2**(8): 584-93.

23. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med* 2004; **350**(16): 1655-64.
24. Chen H-M, Chen F-P, Yang K-C, Yuan S-S. Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status. *JAMA Network Open* 2019; **2**(3): e190429-e.
25. Takegahara N, Kim H, Choi Y. Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. *Experimental & Molecular Medicine* 2024; **56**(2): 264-72.
26. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Res* 2010; **70**(14): 5649-69.
27. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. *Nat Rev Cancer* 2011; **11**(6): 411-25.
28. Trabert B, Geczik AM, Bauer DC, et al. Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B∼FIT Cohort. *Cancer Epidemiol Biomarkers Prev* 2021; **30**(11): 2030-7.
29. Dallal CM, Lacey JV, Jr., Pfeiffer RM, et al. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ∼ FIT Cohort. *Horm Cancer* 2016; **7**(1): 49-64.
30. Dallal CM, Tice JA, Buist DS, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. *Carcinogenesis* 2014; **35**(2): 346-55.
31. Dallal CM, Brinton LA, Bauer DC, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. *Endocr Relat Cancer* 2013; **20**(1): 151-60.
32. Fabiano V, Mandó P, Rizzo M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. *JCO Global Oncology* 2020; (6): 639-46.
33. Pan Y, Lin Y, Mi C. Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis. *Ann Transl Med* 2021; **9**(16): 1340.
34. Yao YB, Zheng XE, Luo XB, Wu AM. Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: a large population-based study. *Am J Transl Res* 2021; **13**(9): 10248-61.
35. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. *South Med J* 1988; **81**(9): 1109-12.
36. Zhang W, Bado IL, Hu J, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. *Cell* 2021; **184**(9): 2471-86.e20.
37. Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. *The Lancet Oncology* 2020; **21**(1): 60-72.
38. Pourhoseingholi MA, Baghestani AR, Vahedi M. How to control confounding effects by statistical analysis. *Gastroenterol Hepatol Bed Bench* 2012; **5**(2): 79-83.
39. Vetter TR, Mascha EJ. Bias, Confounding, and Interaction: Lions and Tigers, and Bears, Oh My! *Anesth Analg* 2017; **125**(3): 1042-8.

40. Nair B. Clinical Trial Designs. *Indian Dermatol Online J* 2019; **10**(2): 193-201.
41. Pietschmann P, Peterlik M. [Pathophysiology of osteoporosis]. *Wien Med Wochenschr* 1999; **149**(16-17): 454-62.
42. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 2022; **33**(10): 2049-102.

Table 1 Characteristics of the cohorts

Characteristics	Low-rirk of osteoporosis n=359	High-risk of osteoporosis n=426	p value
Age, median(IQR)	45 (41-48)	64 (59-70)	<0.01
Menopause (%)	109(30.4)	351(82.4)	<0.01
Stage			0.33
2	263	325	
3	96	101	
Nodal involvment (%)	227(63.2)	251(58.9)	0.22
Radiation therapy (%)	171(47.6)	191(44.8)	0.43
Perioperative chemothepray (%)	245(68.2)	199(46.7)	<0.01
Endcrine therapy (%)	336(93.6)	399(93.7)	0.96
Osteoporosis risk score [0-1]	0.04±0.03	0.44±0.24	<0.01

IQR; interquartile range, osteoporosis risk is the highest when the score of 1

Table 2 Cox proportional models for recurrence of bone metastasis in women after definitive surgery for early-stage breast cancer

	Harzard ratio	95% confidential interval	*P value*
Risk of osteosporosis score			
Enrolled women	4.23	1.71-19.13	<0.01
Premenopausal women	8.69	1.86-30.78	<0.01
Postmenopausal women	2.87	1.01-7.99	0.04
Stage 3			
Enrolled women	3.32	2.14-5.16	<0.01
Premenopausal women	3.11	1.57-6.12	<0.01
Postmenopausal women	3.40	1.90-6.06	<0.01

adjusted by age, menopause, perioperative chemotherapy

Figure 1 Study design



Figure 2. Univariate analyses stratified with menopausal status



Survival analysis representing the proportion of bone metastasis free patients based risk of osteoporosis score in a) whole enrolled women, b) premenopausal women, and c) postmenopausal women. HRO: high-risk of osteoporosis, LRO; low-risk of osteoporosis

Figure 3 Validity for the risk of osteoporosis



a) Conduction rate of DXA in premenopausal and postmenopausal women. b) Correlation analysis between T-score and the risk of osteoporosis in postmenopausal women. c) A formula predicting bone metastasis within 5 years after surgery for early-stage breast cancer. d) receiver operating characteristics curves of the formula predicting bone metastasis in premenopausal women. DXA: dual-energy Xray absorptiometry, Pre-meno: premenopausal women, Post-meno: postmenopausal women

Graphical Abstract